OncoMatch/Clinical Trials/NCT05946213
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Is NCT05946213 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies non-drug interventions for prostate adenocarcinoma.
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage CT3A, CT3B, STAGE III, STAGE IVA (AJCC 8th edition)
Grade: Gleason Score 8-10 (Gleason)
cT3a-T3b by digital exam or imaging (AJCC 8th edition); cT4 by imaging or on digital rectal exam is not allowed; Gleason Score of 8-10
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: androgen deprivation therapy (LHRH agonist, oral anti-androgen) — prostate cancer
Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both luteinizing hormone releasing hormone [LHRH] agonist and oral anti-androgen) is <= 185 days prior to registration
Cannot have received: radiation therapy
Exception: would result in overlap of radiation therapy fields
No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
Cannot have received: radical prostatectomy
No prior radical prostatectomy
Cannot have received: ablative or focal therapy to the prostate (transrectal high-intensity focused ultrasound, transurethral high-intensity focused ultrasound, laser ablation, cryotherapy, irreversible electroporation, vascular-targeted photodynamic therapy)
No prior ablative or focal therapy to the prostate (including, but not limited to, transrectal or transurethral high-intensity focused ultrasound [HIFU], laser ablation, cryotherapy, irreversible electroporation [IRE], and vascular-targeted photodynamic therapy)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham Cancer Center · Birmingham, Alabama
- The Kirklin Clinic at Acton Road · Birmingham, Alabama
- Lewis and Faye Manderson Cancer Center · Tuscaloosa, Alabama
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- Kaiser Permanente-Deer Valley Medical Center · Antioch, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify